文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.

作者信息

Cuffel Alexis, Allain Vincent, Faivre Lionel, Di Blasi Roberta, Morin Florence, Vercellino Laetitia, Chevalier Mathieu F, Desnoyer Aude, de Jorna Romain, Madelaine Isabelle, Parquet Nathalie, Brignier Anne C, Thieblemont Catherine, Larghero Jerome, Caillat-Zucman Sophie, Mebarki Miryam

机构信息

Laboratoire d'Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.

Pathophysiology and Immunotherapy, Institut National de la Santé et de la Recherche Médicale, UMR976 Human Immunology, Paris, France.

出版信息

Blood Adv. 2022 Aug 9;6(15):4657-4660. doi: 10.1182/bloodadvances.2022007057.

DOI:10.1182/bloodadvances.2022007057
PMID:35728051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9636323/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/560e/9636323/5516dbea9613/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/560e/9636323/3afd3030765c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/560e/9636323/5516dbea9613/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/560e/9636323/3afd3030765c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/560e/9636323/5516dbea9613/gr2.jpg

相似文献

[1]
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.

Blood Adv. 2022-8-9

[2]
Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.

Transfusion. 2022-8

[3]
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.

Am J Hematol. 2019-1-24

[4]
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.

Cytotherapy. 2022-9

[5]
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.

Curr Oncol Rep. 2019-3-27

[6]
The promise of CAR T-cell therapy in aggressive B-cell lymphoma.

Best Pract Res Clin Haematol. 2018-9

[7]
CARTs to the rescue: therapeutic potential of chimeric antigen receptor T-cells in patients with B-cell malignancies.

Leuk Lymphoma. 2013-2

[8]
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.

Cytotherapy. 2020-2-13

[9]
Are all chimeric antigen receptors created equal?

J Clin Oncol. 2015-2-20

[10]
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Lancet Oncol. 2021-10

引用本文的文献

[1]
Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study.

Sci Rep. 2025-8-14

[2]
Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma.

Blood Neoplasia. 2024-10-24

[3]
Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy.

EJHaem. 2025-5-5

[4]
CGT 4.0: a distant dream or inevitable future? Smart process automation is critical to make efficient scalability of CGT manufacturing a reality.

Front Bioeng Biotechnol. 2025-3-19

[5]
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.

Nat Rev Clin Oncol. 2025-4

[6]
Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma.

Hematol Oncol. 2025-1

[7]
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.

Blood Adv. 2025-2-25

[8]
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Front Cell Dev Biol. 2024-11-18

[9]
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.

Front Pediatr. 2024-1-12

[10]
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.

Blood Adv. 2024-1-23

本文引用的文献

[1]
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.

Cancer Discov. 2021-9

[2]
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Blood Adv. 2020-11-24

[3]
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Blood Adv. 2020-10-13

[4]
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.

Cancer Discov. 2020-4

[5]
Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.

Cancer Discov. 2019-1-10

[6]
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2018-12-1

[7]
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Nat Med. 2018-4-30

[8]
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med. 2017-12-28

[9]
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

N Engl J Med. 2017-12-28

[10]
Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.

Sci Transl Med. 2016-1-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索